Guselkumab

• CAT Number: I044214
• CAS Number: 1350289-85-8
• Purity: ≥95%

Guselkumab（Cat No.:I044214）is a fully human monoclonal antibody that selectively targets interleukin-23 (IL-23) by binding to its p19 subunit. By inhibiting IL-23 signaling, guselkumab modulates the inflammatory response involved in autoimmune skin diseases. It is approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. Administered via subcutaneous injection, guselkumab helps reduce skin lesions, joint inflammation, and related symptoms with a favorable safety profile. Its high specificity for IL-23 makes it an effective long-term therapy, offering improved disease control and enhanced quality of life for affected patients.